Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
The U.S. FDA has granted an additional approval to AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo's ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) Enhertu (trastuzumab deruxtecan) for HER2-low breast cancer . The approval is the first for a targeted therapy for the breast can...
The U.S. Food and Drug Administration (FDA) on Friday approved the cancer medication Enhertu developed by AstraZeneca ( NASDAQ: AZN ) and its Japanese partner Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) for adult patients with HER2-low breast cancer. HER2 is a t...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2022 Q2 earnings call. For further details see: Daiichi Sankyo Company, Limited 2022 Q2 - Results - Earnings Call Presentation
Daiichi Sankyo Company, Limited (DSKYF) Q1 2022 Earnings Conference Call July 29, 2022, 2:00 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Wataru Takasaki - Executive Officer, Head, R&D Division Conferen...
Daiichi Sankyo Co. ( OTCPK:DSKYF ): Q1 GAAP EPS of ¥730.50. Revenue of ¥280.32B (+6.2% Y/Y). For further details see: Daiichi Sankyo Co. GAAP EPS of $730.50, revenue of $280.32B beats by $278.31B
The shares of cancer-focused biotech Seagen ( NASDAQ: SGEN ) have lost ~4% in the morning hours Monday to record the biggest intraday loss since May after the Wall Street Journal reported a potential delay for company’s widely expected buyout deal with Merck ( MRK )...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. We are closely watching corporate results to determine the near-term outlook for international equities. How co...
Merck's ( NYSE: MRK ) potential $40 billion acquisition of Seagen ( NASDAQ: SGEN ) is not likely to happen ahead of the pharma co.'s earnings later this month, though talks still remain on track. The WSJ reported earlier this month that Merck ( MRK ) was targetin...
Update 4:30pm: Adds background from sell side analyst. Seagen ( NASDAQ: SGEN ) ticked up 1.3% after the Patent Trial and Appeal Board upheld a patent in a dispute the company had with Daichi Sankyo ( OTCPK:DSKYF ), according to a PTAB r uling. The PTAB ruling...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...